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Abstract  
 
One hundred twenty-five million pregnant women are at risk for contracting malaria, a 
preventable cause of maternal and infant morbidity and death.  Malaria parasites contribute to 
adverse pregnancy and birth outcomes due to their preferential accumulation in placental 
intervillous spaces.  Pregnant women are particularly vulnerable to malaria infections, and 
malaria infections during pregnancy put their fetuses at risk.  Malaria in pregnancy is associated 
with anemia, stillbirth, low birth weight and maternal and fetal death.  We review the challenges 
to diagnosing malaria in pregnancy, as well as strategies to prevent and treat malaria in 
pregnancy.  Finally, we discuss the current gaps in knowledge and potential areas for continued 
research.  
 
  
Introduction 
Globally, an estimated 125 million pregnant women reside in areas where they are at 
risk of contracting malaria in pregnancy (MIP), and MIP remains an important preventable cause 
of adverse birth outcomes.1  Although there are five species of malaria that infect humans, two 
main species of Plasmodium contribute to adverse maternal and fetal outcomes in pregnancy, 
P. falciparum and P. vivax. In sub-Saharan Africa, where the majority of adverse birth outcomes 
attributable to malaria occur, P. falciparum is the dominant species. However, over half of 
pregnancies that are potentially exposed to malaria occur in Southeast Asia and the Western 
Pacific where P. falciparum and P. vivax coexist.  Co-existence of P. falciparum and P. vivax 
also occurs in South America, where 3% of the global total of women at risk for MIP reside.1  
Over the past decade, there has been significant progress in reducing the global 
prevalence of P. falciparum, particularly in Africa. However, women remain at high risk of MIP, 
with over 50% of women in high transmission areas having P. falciparum detected in peripheral 
blood at presentation to antenatal care.2, 3  This high prevalence of disease results from an 
increased risk of contracting malaria among pregnant compared to non-pregnant women.  
Women who are younger, malnourished, primigravidae/secundigravidae, lack immunity to 
pregnancy-associated malaria, or living with HIV are at the highest risk of malaria-associated 
adverse pregnancy outcomes.4, 5  
Pathophysiology of Malaria in Pregnancy 
MIP contributes to adverse pregnancy outcomes, at least in part, due to the preferential 
accumulation of parasites in the placental intervillous space. Placental sequestration is common 
in infections with P. falciparum because malaria parasites export a protein, VAR2CSA, to the 
red blood cell membrane that facilitates adherence to chondroitin-sulfate A (CSA) on syndecan-
1, which is anchored in placental tissue.6 This interaction is associated with the recruitment, 
retention and activation of mononuclear cells in the placenta—and is thought to mediate 
malaria’s effect on birth outcomes.7  Maternal antibodies against VAR2CSA are protective.5  P. 
vivax can also lead to placental changes, but to date no studies have unequivocally 
documented the sequestration of P. vivax infected erythrocytes in the placenta.8 
A number of histological changes in P. falciparum infected placentae have been 
described, including the infiltration of mononuclear cells, deposition of malaria pigment, 
thickening of the trophoblast basement membrane, syncytial knotting, and complement 
deposition.9-11 Inflammation in the placenta has been linked to impaired transplacental transport 
of glucose12 and amino acids,13 and disruption of the insulin-like growth hormone axis.14 
Impaired nutrient transport across the placenta may be further exacerbated by altered placental 
angiogenesis15 leading to changes in both the villous architecture16 and surface area for nutrient 
exchange, as well as impaired uteroplacental blood flow.15, 17 These histologic and functional 
changes likely contribute to impaired fetal growth. Longitudinal Doppler data support the idea 
that malaria in the first half of pregnancy can lead to changes in umbilical artery blood flow and 
fetal growth in pregnancy, and this is affected by both gravidity and nutritional status.18  
Risk Factors for Malaria in Pregnancy 
Environmental, parasite, and maternal factors influence the severity of MIP.  In areas 
where malaria transmission is high, the primary burden of malaria is in primigravidae, whereas, 
in areas of low transmission, all gravidities are at risk. In areas of high transmission, 
primigravidae develop antibodies to VAR2CSA protein produced by malaria parasites, and are 
partially protected during subsequent pregnancies; this tends not to happen in areas of low 
transmission.19 Overall, pregnant women living in areas with low or unstable (episodic) 
transmission have little or no immunity to malaria and are at a two-to-three times higher risk of 
severe disease compared to non-pregnant controls.20 P. falciparum has typically been 
associated with more severe MIP than P. vivax, although P. vivax is more likely to occur in a 
mother with little acquired immunity.21 Maternal age and gravidity also play a role in the severity 
of MIP. Younger mothers are at greater risk for severe malaria infection compared to older 
mothers, who appear to have some protection from severe disease.4 In high transmission areas, 
such as sub-Saharan Africa, primigravidae and secundigravidae are at greater risk for severe 
malaria infection compared to multigravidae, but this is not true in areas of low transmission, 
where multigravidae have not had prior malaria exposure nor developed immunity.22  
Malnourished pregnant women are at increased risk for adverse birth outcomes with 
MIP.23  A meta-analysis using individual patient data from 14,633 pregnancies from Africa and 
the Western Pacific between 1996-2015 showed that malaria and malnutrition are common 
exposures, with 35% of women having either of those exposures.  Pregnant women with 
malnutrition and malaria were at an increased risk of LBW compared to women with only 1 of 
those risk factors.24 Recent data suggests reduced L-arginine intake is one mechanism through 
which malnutrition contributes to low birth weight with both nutritional survey data25 and 
preclinical models26 suggesting that L-arginine supplementation may reduce preterm birth25 and 
increase fetal viability, placental vascularization, and birth weight.26  
Burden of Malaria 
Maternal Effects 
The clinical effects of malaria on pregnant women vary from no symptoms to severe 
anemia and death. Women living in areas of low malaria transmission who have a lower degree 
of acquired immunity are more likely to experience complications such as renal failure, 
pulmonary edema, and cerebral malaria.27 Despite this, the overall maternal mortality rate is 
similar in low-transmission areas (0.6-12.5%) compared to malaria-endemic areas (0.5-23%).4 
More research is warranted on the topic of malaria-related mortality during pregnancy, as the 
current data are limited and inconsistent. 
Maternal anemia is one of the most common symptoms of MIP.  Plasmodium causes 
anemia through hemolysis, increased splenic clearance of erythrocytes, and reduced red blood 
cell production. While severe anemia during pregnancy (hemoglobin <7 g/dL) is often 
multifactorial with significant nutritional components, malaria can play an important role.28 In one 
estimate in sub-SaharanAfrica, the population attributable fraction of malaria to severe anemia 
during pregnancy was 26%.4 For endemic areas with a 5% baseline prevalence of severe 
anemia, epidemiological modeling predicts malaria-induced anemia to contribute to nine 
maternal deaths per 100,000 live births.4   However, in a population-based study in the 
Democratic Republic of the Congo, malaria played little or no role as a driver of anemia during 
pregnancy.29 
Pregnant women are three times more likely to be affected by severe malaria.30 The 
World Health Organization defines severe malaria as parasitemia with evidence of end organ 
dysfunction (Table 1). The presenting features of severe malaria can include severe anemia, 
hypoglycemia, acute respiratory distress syndrome, renal failure and cerebral malaria.30  The 
median mortality of severe MIP is 39% (range 8-100%).30  Severe malaria must be treated 
promptly with intensive care and parenteral antimalarial medication to reduce mortality.31   
Fetal Effects 
Malaria is an important cause of stillbirth throughout endemic areas (Figure 1). MIP 
contributes to 12-20% of stillbirths in endemic regions of sub-Saharan Africa, with lower rates if 
the mother undergoes treatment.32 P. falciparum detection both in peripheral blood samples or 
placental samples at delivery nearly doubles the odds of stillbirth (odds ratio 1.81 and 1.5, 
respectively).32  Stillbirth risk is higher in areas with low to intermediate endemicity compared to 
areas of high endemicity.33 The risk of stillbirth can be modified with appropriate malaria 
intervention efforts. For example, the use of insecticide-treated bed nets (ITN) is associated with 
lower rates of placental malaria and stillbirth (risk ratio 0.67 [95% CI 0.45 to 1.00] for stillbirth).34  
MIP increases the risk of low birth weight (LBW), and approximately 20% of cases of 
LBW in malaria-endemic areas are attributed to placental infection with malaria (Figure 1).35 A 
mother with a malaria-infected placenta is twice as likely to have a baby with LBW.36 LBW in 
turn is associated with higher infant mortality rates. In Africa, LBW has been associated with a 
three - to 20-fold increase in the probability of infant mortality.36, 37 Parity is an important factor in 
LBW. Primigravidae with MIP have two to seven higher odds of LBW and mortality than 
multigravidae.38 The timing of infection also seems to play a role in infant size. Second-trimester 
infection is more likely to result in LBW than third-trimester infection; but data on first-trimester 
infection are limited.39   
MIP causes LBW due to both intrauterine growth restriction (IUGR) and prematurity. Up 
to 70% of IUGR in endemic areas is due to malaria, presumably as a result of impaired oxygen 
and nutrient delivery to the fetus.35, 36 The contribution of malaria to preterm birth is also 
substantial, with up to 36% of prematurity in malaria-endemic areas attributable to Plasmodium 
infection. Prematurity may result from the host’s immune response to malaria parasites 
triggering early labor.33 These adverse fetal effects are species specific, as P. ovale and P. 
malariae species are not associated with adverse birth outcomes.   
Congenital Malaria 
Congenital malaria is defined as the identification of asexual P. falciparum parasites in 
the cord blood or peripheral blood of an infant during the first 7 days of life.40 The true 
prevalence of congenital malaria is uncertain. While the prevalence was previously thought to 
be between <1% and 6%,40 more recent studies have demonstrated a prevalence rate up to 
33% in high-endemicity areas; but it is not clear how many of these congenital infections persist 
and cause clinical illness.41 Most descriptive reports of congenital malaria are from infants who 
are born in non-endemic areas to mothers with a history of travel to endemic areas. Infant 
symptoms include fever associated with hepatosplenomegaly, hemolytic anemia, 
thrombocytopenia, and feeding intolerance.41 These infants often become symptomatic between 
10 and 30 days of life, although they can present later. Their symptoms may progress rapidly 
and can be fatal.27, 42 Because, much of the literature on congenital malaria is derived from case 
reports, more research is needed to better understand the epidemiology and pathophysiology of 
congenital malaria. 
Effects in Early Childhood 
Offspring are affected by placental malaria into childhood, (Figure 1). Prenatal malaria 
exposure is associated with an increased risk of early malaria infection in children as young as 
four to six months of age.40 Placental parasitemia may increase the risk of malaria infections in 
infancy and childhood through several mechanisms. For example, MIP might interfere with 
maternal antibody passage to offspring, compromising the immunity of the fetus and newborn, 
making the offspring vulnerable to early malaria infections.40  In utero exposure to malaria 
induces the development of Treg cells that lead to fetal immune tolerance to malaria antigens 
that persists into childhood.43  Placental malaria has been associated with subsequent 
susceptibility to non-malaria infections, including measles and tetanus, suggesting additional 
effects on infant immunity that may be due to the obstruction of antibody passage across the 
placenta.44 Acute placental malaria infection has been associated with increased one-year 
mortality in infants45 and decreased length and weight gain in the first year of life.46, 47 MIP is 
also associated with anemia during infancy and the infant’s risk for anemia with maternal 
peripheral parasitemia at delivery is 11.8% and 9.2% with placental malaria infection.48  
Diagnosis 
 The diagnosis of MIP can be challenging due to placental sequestration of parasitized 
erythrocytes, low circulating levels of parasites and limited resources in malaria endemic areas 
for advanced diagnostic techniques. Microscopic identification of malaria from the blood by an 
experienced and well-equipped technician remains the gold standard for malaria diagnosis.49 
However, rapid diagnostic tests (RDTs) that test for malaria antigens, like histidine-rich protein-1 
(PfHRP2), are another option for malaria diagnosis.49-51 RDTs are easier than microscopy to 
perform in low-resource settings, because they are not dependent on highly trained technicians 
in well-equipped laboratories.  Therefore, RDTs might be the most appropriate point of care 
testing among symptomatic mothers in low-resource settings.31, 50  However, the use of RDTs 
might be insufficient in diagnosing MIP among mothers with asymptomatic infection, because 
RDTs require a higher circulating parasite burden than microscopy for detection.52  RDTs are 
also insufficient to detect low amounts of circulating parasites because of placental 
sequestration.  In research studies, the gold standard for malaria diagnosis has been placental 
histopathology, but it is not practical in many field sites.53, 54  Using microscopy of placental 
blood as the referent, the sensitivity of RDTs is 81% (95% CI 55-93) and the specificity is 94% 
(95% CI 76-99).31  Molecular techniques, such as polymerase chain reaction (PCR) diagnosis, 
have increased sensitivity of diagnosis when compared to microscopy of placental blood to 94% 
(95% CI 86-98), but specificity of 94% (95% CI 86-98).31   A new generation of ultrasensitive 
RDT’s is now being developed and might mitigate these diagnostic problems.55 
Prevention and Treatment 
Prevention Strategies in Africa 
In malaria-endemic areas in Africa, a combination of vector control (preventing exposure 
to mosquitos) and chemoprevention (preventive medication-based treatment) strategies are 
used to prevent MIP.  The World Health Organization (WHO) recommends a combined 
approach using insecticide treated bed nets (ITNs) to reduce exposure to mosquitoes carrying 
malaria and chemoprevention.56 ITNs work by providing a physical barrier from mosquitoes, and 
repelling or killing susceptible mosquitoes, which reduces mosquito density and maintains the 
nets’ effectiveness even after the integrity of the barrier is compromised.57  The use of ITNs in 
Africa have been shown to reduce LBW by 23%, miscarriages and stillbirths by 33%, and 
placental parasitemia by 23%.58 Despite the proven efficacy of ITNs, uptake was estimated at 
only 39% in Africa between 2009 and 2011.59  Since that time, ITN use has steadily increased, 
and an estimated 61% of pregnant women at risk for malaria slept under an ITN in 201756, 
(Figure 2).   Malarial resistance to pyrethroids, the most commonly used insecticide in ITNs has 
been reported across sub-Saharan Africa and might impair future efficacy.57  
Spraying the walls of households with insecticide to reduce human exposure to 
mosquitos, a procedure known as indoor residual spraying (IRS) is part of a comprehensive 
vector control program.  Globally, IRS usage has declined and only 3% of the population at risk 
was protected by IRS in 2017, which might be related to a switch in insecticide from pyrethroids 
to more expensive chemicals.56  IRS has been shown to improve outcomes of MIP, with women 
protected by IRS having lower incidence of MIP and lower risk of placental malaria.60, 61 When 
women were protected during greater than 90% of the time of their pregnancies,  women had 
lower risk of preterm birth (risk ratio 0.35, 95% CI, 0.15-0.84).60 IRS is an important part of a 
comprehensive vector control program and might contribute to improved birth outcomes in 
malaria-endemic regions.     
Chemoprevention strategies have been successfully used to prevent adverse health 
outcomes associated with MIP. The most efficacious of these strategies uses a technique of 
intermittent preventive treatment in pregnancy (IPTp).  IPTp consists of providing monthly doses 
of anti-malarial medication to all pregnant women starting in the second trimester. Women who 
receive at least 2 courses of IPTp have a relative risk reduction of 40% for moderate to severe 
anemia, 61% for antenatal parasitemia, 55% for placental parasitemia and 27% for low 
birthweight.62  Since 2012, the WHO has recommended monthly IPTp to reduce the incidence of 
these complications of pregnancy.63 However, despite WHO recommendations, in 2017, only 
22% of pregnant women received three or more doses of IPTp in Sub-Saharan Africa (Figure 
3).64 
 Sulfadoxine-pyrimethamine (SP) has been the drug of choice for IPTp in women who are 
HIV-negative.65  Plasmodium resistance to SP has emerged through multiple mutations in the P. 
falciparum dihydrofolate reductase (Pfdhfr) and dihydropteroate synthetase (Pfdhps), with 
penetrance of this haplotype in some areas of greater than 90%.66  Due to increasingly more 
resistant organisms, IPTp with SP is less effective at inhibiting parasite growth and preventing 
fetal growth restriction.66  In light of increasing resistance, alternative strategies for 
chemoprevention are being tested, including IPTp with alternative medications and strategies of 
intermittent screening and treatment in pregnancy (ISTp).  ISTp strategies use RDTs to 
diagnosis MIP at multiple time points and treat only when RDTs are positive.  However, these 
strategies depend on accurate diagnosis of MIP and have not been proven to be effective 
alternatives to IPTp-SP even in highly resistant areas.66  IPTp with dihydroartemisinin-
piperaquine (DP) might be a promising alternative to IPTp-SP, but more research is needed in 
this area.66  
Prevention Strategies Outside of Africa 
In South America and Asia, where malaria transmission is typically lower than in Africa, 
data on traditional chemoprophylaxis is limited.  Prophylaxis with mefloquine or chloroquine has 
been efficacious for preventing MIP in pregnant women in Thailand.67, 68  Other 
chemoprophylactic strategies employed outside of Africa have included monthly IPTp-SP with 
azithromycin and ISTp-SP and artesunate. These strategies show promise in the reduction of 
low birth weight or maternal parasitemia.   
Treatment of uncomplicated malaria 
 All MIP infections should be treated promptly to avoid complications to the mother and 
fetus.31  To ensure safety of treatment in pregnancy, the WHO recommends trimester-specific 
and species-specific treatment strategies for uncomplicated malaria (Table 1).  For first trimester 
treatment of P. falciparum, the WHO recommends a 7-day treatment course of quinine with 
clindamycin, and second line treatment includes artemisinin-based combination therapy (ACT) 
or oral artesunate with clindamycin.65  First trimester treatment of uncomplicated non-falciparum 
malaria consists of chloroquine or quinine for chloroquine-resistant infections.   
 Second and third trimester treatment of uncomplicated malaria follows the same 
guidelines as treatment for malaria in non-pregnant adults.31  Therefore, first line treatments with 
ACTs can be used in MIP.  ACTs include a short-acting artemisinin component and a longer 
acting partner drug, such as SP.69  The potent artemisinin reduces the number of parasites 
quickly and the longer acting partner drug acts on the remaining parasites and provides a post-
treatment prophylactic effect, preventing new infections.69  ACTs have achieved cure rates as 
high as 99.2% for uncomplicated MIP without demonstrating significant safety concerns.70 
Treatment of Severe Malaria 
Severe malaria has historically been attributed to infections with P. falciparum, but more 
recent evidence has included P. vivax as a significant contributor to severe malaria.30  For 
pregnant patients with severe malaria, the WHO recommends the same treatments for both P. 
falciparum and P. vivax infections. The WHO also recommends treatment with primaquine after 
delivery to achieve cure and prevent relapses by eradicating P. vivax sequestered in the liver, 
(Table 1).30   
Artemisinins are the most efficacious drugs for severe MIP after the first trimester.  
Because they are embryotoxic and teratogenic in animal studies, the WHO does not 
recommend their use in the first trimester for uncomplicated malaria.  However, their use is 
recommended even in the first trimester in cases of severe malaria because of the high risk of 
maternal mortality.30  Data on the use of artemisinins in the first trimester in humans show no 
associated increased risk of adverse pregnancy outcomes.30 Long-term neurodevelopmental 
studies are needed to evaluate the safety of different drug combinations on child development. 
Quinine is an alternative to artemisinin that has been used for centuries for the treatment 
of malaria.  Although it is not considered embryotoxic or teratogenic in animal studies, it is less 
well-tolerated in humans.30 Quinine can prolong the cardiac QT interval and is associated with 
tinnitus, headache, blurred vision, altered auditory acuity, nausea, diarrhea, and, rarely, massive 
hemolysis.65  These side effects reduce compliance with treatment regimens and lead to higher 
levels of treatment failure.30  
Vaccines 
 An efficacious vaccine against malaria could be of particular benefit for pregnant women.   
One vaccine, RTS,S, is now approved by the European Medicines Agency, but is only modestly 
effective.71   Efforts are also underway to develop a vaccine targeting the VAR2CSA antigen to 
protect women against pregnancy-associated malaria.72  
Co-Infection with HIV 
Co-infections with malaria and HIV worsen morbidity and mortality for each disease, 
possibly due to alterations in the balance between the immune response to malaria and 
stimulation of viral replication.73 MIP is associated with a two-fold higher HIV viral load.  
Conversely, women living with HIV experience more placental and peripheral malaria, higher 
parasite densities, more frequent febrile illnesses, more severe anemia and worse birth 
outcomes compared to non-HIV infected mothers with MIP.73  Chemoprevention for women 
living with HIV in malaria-endemic areas includes daily co-trimoxazole.  SP is discouraged for 
chemoprevention due to potential adverse drug reactions between SP and co-trimoxazole.74  
Although pregnant women living with HIV have the greatest risk of severe MIP, treatment 
strategies for severe malaria in conjunction with HIV treatments have not been well studied.30, 73  
The WHO recommends against the use of zidovidine or efavirenz and the use of artesunate 
amodiaquine due to neutropenia and hepatotoxicity respectively.65  Pregnant women receiving 
highly active antiretroviral therapy regimens should receive quinine when cardiac monitoring is 
available. 
 
 
Conclusions 
Malaria is among the most common and easily preventable causes of poor birth 
outcomes in the world.  IPTp and ITNs distribution programs have helped decrease malaria risk 
among pregnant women in many parts of the world.  However, greater efforts are needed 
especially in light of increasing drug and insecticide resistance. A better understanding of the 
pathogenesis of malaria during pregnancy could lead to the development of new interventions to 
prevent its health consequences.   
 
Gaps in Knowledge (sidebar) 
• What are the mechanisms by which malaria during pregnancy affects fetal growth? 
• What is the natural history of congenital malaria? 
• How can we increase uptake of IPTp and ITN’s by pregnant women?  
• When is the optimal gestational age to start IPTp?    
• How can we enable women to begin IPTp earlier during pregnancy? 
• When malaria prevalence drops, when is it appropriate to stop IPTp? 
• When high levels of resistance to SP develop, what should be done to protect pregnant 
women from malaria? 
• Will it be possible to vaccinate primigravidae against pregnancy-associated malaria? 
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Table 1: Treatment Strategies for MIP 
 
Severity Uncomplicated Malaria Severe Malaria 
Definition  Symptoms of malaria and positive parasitological 
test (microscopy or RDT) but no features of severe 
malaria 
Parasitemia and one of the 
following (not caused by another 
etiology):  
1) Impaired consciousness 
2) Prostration 
3) Multiple convulsions 
4) Acidosis 
5) Hypoglycemia 
6) Severe malarial anemia 
(Hemoglobin <7 g/dL) 
7) Renal Impairment 
8) Jaundice 
9) Pulmonary Edema 
10) Significant bleeding 
11) Shock 
12) (P. falciparum only) 
Hyperparasitemia >10% 
 
Treatment First Trimester Second and Third 
Trimester 
All Trimesters 
P. falciparum Quinine and 
clindamycin x 7 days 
 
 
Artemisinin-based 
combination therapy 
(ACT) for 3 days, Options 
include 
1) artemether + 
lumefantrine 
2) artesunate + 
amodiaquine 
3) artesunate + 
mefloquine 
4) artesunate + SP 
5) dihydroartemisinin 
+ piperaquine 
Treatment for all Plasmodium 
species 
 
IV or IM artesunate at least 24 
hours then ACT for 3 days 
 
Add primaquine in areas of low-
transmission 
Non-
falciparum 
Chloroquine or  
If chloroquine-resistant: 
quinine  
 
Add weekly 
chemoprophylaxis with 
chloroquine through 
pregnancy and 
breastfeeding 
 
Add Post-
delivery/lactating: 
treatment with 
primaquine x 14 days 
 
ACT or Chloroquine  
If chloroquine-resistant: 
ACT  
 
Add weekly 
chemoprophylaxis with 
chloroquine through 
pregnancy and 
breastfeeding 
 
Add Post-
delivery/lactating: 
treatment with primaquine 
x 14 days 
 
 
 
 
 
Figure 1: Effects of malaria in pregnancy through the life course 
 
 
IUGR = Intrauterine growth retardation.  Reprinted with permission (4).  
 
 
  
Figure 2: Uptake of ITN: Percentage of the population in Sub-Saharan Africa at risk for malaria 
with access to ITN and using ITNs.  
 
 
ITN: insecticide-treated bed nets Sources: World Health Organization and Malaria Atlas Project. 
Reprinted with permission (56). 
 
 
 
 
 
 
  
Figure 3: Uptake of IPTp: Percentage of pregnant women receiving IPTp, by dose in Sub-
Saharan Africa, 2010-2017.  
 
 
 
ANC: antenatal care, IPTp: intermittent preventive treatment in pregnancy, listed by dose. 
Sources: National Malaria Programme, World Health Organization, US Centers for Disease 
Control and Prevention. Reprinted with permission (56). 
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